NSNaoki Segawa

Naoki Segawa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Naoki Segawa has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Surgical correction of buried penis after traffic accident – a case report

    by Hiroshi Masuda, Haruhito Azuma, Naoki Segawa, Yusaku Iwamoto, Teruo Inamoto, Noboru Takasaki, Yoji Katsuoka

    Buried penis, most commonly seen in children, is particularly debilitating in adults, resulting in inability to void while standing and it also affects vaginal penetration. We report a case of buried penis due to a traffic accident, which caused dislocation of the fractured pubic bone that shifted inside and pulled the penis by its suspensory ligament. A 55-year-old man was admitted to our hospital with a chief complaint of hidden penis while in the sitting position. He had suffered a pelvic fracture in a traffic accident four years previously, and his penis was covered with suprapubic fat when he was in a sitting position. He was unable to have sexual intercourse. We performed a penile lengthening procedure, including inverse V-Y-plasty of the dorsal skin of the penile root, suspensory desmotomy and fat removal, under general anesthesia. There was a good cosmetic result with satisfactory penile erection, which allowed successful sexual intercourse after surgery. We performed penile elongation surgery with inverse V-Y-plasty of the dorsal skin of the penile root, suspensory desmotomy, and fat removal. Surgical treatment of buried penis achieves marked aesthetic and functional improvement, and benefits the majority of patients, resulting in satisfactory erection and successful sexual intercourse.


  • Open Access

    Telomerase activity in renal cell carcinoma by modified telomeric repeat amplification protocol assay.

    by Naoki Segawa, Kazuo Gohji, Haruhito Azuma, Yusaku Iwamoto, Kenji Ohnishi, Yoji Katsuoka


    • 15 August 2001
      • Vol. 61  (16) , 6060-3

    Phosphorylation of mitogen-activated protein kinase is inhibited by calcitonin in DU145 prostate cancer cells.

    by N Segawa, M Nakamura, Y Nakamura, I Mori, Y Katsuoka, K Kakudo

    One of the causes of insensitivity to androgen ablation therapy in prostate cancer is thought to be attributable to elevated neuropeptides secreted by neuroendocrine cells in the tumor mass. Calcitonin (CT), one of these neuropeptides, is reported to be associated with the growth of prostate cancer. There is an increase in mitogen-activated protein (MAP) kinase activation as prostate cancer progresses to a more advanced and androgen-independent disease. We examined the effect of CT on signal transduction and the relation between CT and early-response genes in the human androgen-insensitive prostate cancer cell line, DU145. The basal phosphorylation level of extracellular signal-regulated kinase 1/2, which is a key kinase in the mediation of growth factor-induced mitogenesis in prostate cancer cells, was constitutively up-regulated. N-[2-(4-bromocinnamyl) aminoethyl]-5-isoquinoline-sulfonamide (H89), a specific inhibitor of protein kinase A, potentiated the effects of more increased phosphorylation of extracellular signal-regulated kinase 1/2. CT induced the inhibition of this MAP kinase phosphorylation, and this effect was completely abolished by pretreatment with H89. Our findings demonstrate that CT caused the inhibition of constitutive MAP kinase phosphorylation in a protein kinase A-dependent manner in DU145. The transient increase of c-fos expression was detected after CT treatment, whereas expression of c-jun RNA was down-regulated after CT treatment. These results suggest that CT may regulate early-response genes, c-fos and c-jun, via a MAP kinase cascade. In conclusion, these findings suggest that DU145 might be a useful model as a therapeutic approach of neuropeptides in androgen-independent prostatic carcinoma.


  • Multiple Pathways of Angiotensin I Conversion and Their Functional Role in the Canine Penile Corpus Cavernosum

    by Yusaku Iwamoto, Keifu Song, Shinji Takai, Mayumi Yamada, Denan Jin, Masato Sakaguchi, Haruhiko Ueda, Yoji Katsuoka, Mizuo Miyazaki


  • Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer

    by Naoki Segawa, Ichiro Mori, Hirotoshi Utsunomiya, Misa Nakamura, Yasushi Nakamura, Liang Shan, Kennichi Kakudo, Yoji Katsuoka

    Androgen, acting via the androgen receptor (AR), is associated with the development and progression of prostate cancer. Anti‐androgen therapy is widely used to manage prostate cancer. However, the conversion of the tumor from a hormone‐sensitive to a hormone‐insensitive status causes such therapy to fail. Several mechanisms have now been put forward for this conversion, including neuroendocrine (NE) differentiation of the tumor cells. In this study, we evaluated the prognostic significance of tumor‐cell proliferation activity, NE differentiation and AR expression. Formalin‐fixed, paraffin‐embedded sections were prepared from 42 patients with adenocarcinoma of the prostate. Using antibodies to AR, the Ki‐67 antigen (MIB‐1), chromogranin A and synaptophysin, immunohistochemical expression of AR, tumor proliferation activity and NE differentiation were analyzed. Our study revealed that AR expression was significantly lower in adenocarcinoma (52.2 ± 27.1%) than in non‐tumorous prostate tissue (68.3 ± 18.3%; P < 0.001). NE differentiation was found in 50% of the tumors, which was correlated with the Gleason score (P < 0.05). An univariate analysis revealed a significant correlation between progression‐free survival with both AR expression (P < 0.01) and proliferation activity (P < 0.001). NE differentiation was not a prognostic factor in this study.


  • Open Access

    Expression of three extracellular matrix degradative enzymes in bladder cancer

    by Kazuo Gohji, Hiroshi Hirano, Masayuki Okamoto, Sohei Kitazawa, Minako Toyoshima, Jian Dong, Yoji Katsuoka, Motowo Nakajima

    The human epithelial mucin MUC1 is over‐expressed in more than 90% of carcinomas of the breast, ovary, and pancreas as well as in some other tumours, making it a potential target for tumour immunotherapy. We have identified several MUC1‐derived peptides mapping outside the variable number tandem repeat region that comply with the peptide‐binding motif for HLA‐A*0201 and that become processed into stable major histocompatibility complex‐peptide complexes as assessed by in vitro assays. In A2/Kb transgenic mice, 3 peptides, namely MUC79–87 (TLAPATEPA), MUC167–175 (ALGSTAPPV) and MUC264–272 (FLSFHISNL) elicit peptide‐specific cytotoxic T lymphocyte (CTL) immunity, which protects these mice against a challenge with MUC1, A2/Kb‐expressing tumour cells. These peptides therefore represent naturally processed MUC1‐derived CTL epitopes that could be used as components in peptide‐based vaccines and for the analysis of anti‐MUC1 CTL responses in A*0201‐positive patients with MUC1‐expressing tumours.